Gilead raises full-year guidance a third time as HIV prevention nearly doubles
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year.
Third guidance raise of the year for Gilead, and the prevention franchise is now doing the heavy lifting as Yeztugo scales. CEO Daniel O'Day framed the Q3 report around a base business that keeps outrunning the company's own forecasts.
Continue ReadingShow less
Gilead Sciences lifted its full-year base business revenue guidance for the third time in 2026 during its Q3 earnings report. That kind of repeated upward revision signals that the company's underlying business is consistently outpacing its own internal forecasts.
The standout driver is HIV prevention, where sales nearly doubled year-over-year, fueled by the scaling of Yeztugo. When a single franchise can nearly double revenue in a year, it shifts from being a growth story to a structural earnings story.
Sponsored
CEO Daniel O'Day framed the results around a base business that keeps running ahead of the company's own projections. Guidance raises are common; three in a single year, totaling $1.6 billion, suggest the forecast-setting process itself is conservative and the upside surprises are not finished.
For investors, the question after a third guidance raise is whether the prevention franchise can sustain this pace or whether the year-over-year comparisons get harder as Yeztugo becomes a larger base. The stock moved up 0.54% following O'Day's comments, a measured reaction that likely reflects the market digesting whether a fourth raise is possible before the year closes.
Sources
Mentioned: GILD